Skip to main content

Karen Basbaum

Senior Vice President, Business Development, Poseida Therapeutics, Inc.

Karen is Poseida’s Senior Vice President, Business Development where she has played a key role in establishing the company’s collaborations with Takeda and Roche as well as a strategic investment by Astellas. Prior to joining Poseida in 2020, she had leadership roles in business development at DNAtrix, Dauntless Pharmaceuticals and Elcelyx and was part of the business development team at Amylin Pharmaceuticals where she worked on numerous transactions, most notably the sale of the company to Bristol Myers Squibb in 2012 for $7B. Earlier in her career, she held various scientific roles in drug discovery at Abbott Laboratories (now AbbVie) and Celgene Corporation (now Bristol Myers Squibb).

Karen holds an MBA from the Paul Merage School of Business at the University of California, Irvine and a Master of Science in Organic Chemistry from Rensselaer Polytechnic Institute. She holds two Bachelor of Science degrees (honors) in Biology and Chemistry from the University of North Dakota.